 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This is a signal that CCCC's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

C4 Therapeutics (CCCC, $3.15) RSI Indicator left the oversold zone on August 28, 2023

C4 Therapeutics, Inc. (NASDAQ:CCCC Get Free Report) has been assigned a consensus recommendation of Hold from the seven research firms that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and...

C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Consensus Recommendation of "Hold" by Analysts

C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives $11.13 Consensus Target Price from Brokerages

C4 Therapeutics, Inc. (NASDAQ:CCCC  Free Report)  Analysts at HC Wainwright reduced their FY2023 earnings per share estimates for C4 Therapeutics in a research report issued to clients and investors on Wednesday, August 9th. HC Wainwright analyst A. Fein now forecasts that the company ...

HC Wainwright Comments on C4 Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:CCCC)

C4 Therapeutics, Inc. (NASDAQ:CCCC  Free Report)  Equities research analysts at Leerink Partnrs boosted their Q3 2023 EPS estimates for shares of C4 Therapeutics in a research note issued to investors on Tuesday, August 8th. Leerink Partnrs analyst C. Liu now forecasts that the company...

Leerink Partnrs Weighs in on C4 Therapeutics, Inc.'s Q3 2023 Earnings (NASDAQ:CCCC)

C4 Therapeutics (NASDAQ:CCCC  Free Report) had its target price reduced by HC Wainwright from $25.00 to $17.00 in a research note issued to investors on Wednesday morning, Marketbeat Ratings...

C4 Therapeutics (NASDAQ:CCCC) Given New $17.00 Price Target at HC Wainwright

C4 Therapeutics, Inc. (NASDAQ:CCCC Free Report) Research analysts at Leerink Partnrs issued their FY2027 earnings per share estimates for shares of C4 Therapeutics in a research note issued on Tuesday, August 8th. Leerink Partnrs analyst C. Liu forecasts that the company will post earnings of $2.75 ...

Leerink Partnrs Comments on C4 Therapeutics, Inc.'s FY2027 Earnings (NASDAQ:CCCC)

C4 Therapeutics, Inc. (NASDAQ:CCCC  Get Free Report) has been given an average recommendation of Hold by the seven research firms that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, three have issued a...

C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives $11.13 Average Price Target from Analysts

Established Exclusive Licensing Agreement for CFT8919, an EGFR L858R BiDAC Degrader, with Betta Pharmaceuticals in Greater China for NSCLC; U.S. IND Cleared Ongoing Phase 1/2 Clinical Trials of CFT7455, an IKZF1/3 MonoDAC Degrader, and CFT8634, a BRD9 BiDAC Degrader, Continue to Progress; Phase 1 ...

C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

C4 Therapeutics, Inc. (NASDAQ:CCCC Get Free Report) has earned a consensus rating of Hold from the seven brokerages that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating ...

Brokerages Set C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target at $9.86

C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA.

Watchers	648
52-Wk Low	$1.79
52-Wk High	$10.42

Market Cap	$89.04M
Volume (M)	1.99M
52-Wk High	$10.42
52-Wk Low	$1.79

CCCC C4 Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals